Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Dec 24, 2012
Neuren IND open for Rett Phase II trial
Dec 20, 2012
Appendix 3B
Nov 30, 2012
Neuren TAP Conference presentation and Fragile X results
Nov 22, 2012
Neuren completes Phase I NNZ2566 study/files Phase II IND
Nov 09, 2012
Amended 2 - Change in substantial holding
Nov 09, 2012
Amended Change in substantial holding
Nov 09, 2012
Change in substantial holding
Oct 31, 2012
Appendix 4C - quarterly
Oct 25, 2012
Response to ASX Price Query
Oct 19, 2012
NNZ2566 selected as Windhover Top 10 Neuroscience Project
1
2
3
4
Next